[1] Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb;37(2):187-92.
[2] Kaczmarczyk MS, Jurkiewicz D, Niemczyk S, Rymarz A. Aural manifestations of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis-diagnosis, symptoms, Treatment. J Clin Med. 2024 Jul 23;13(15):4298.
[3] Cao B, Robinson JE, Winget M, Hunt MH, Carlson R, et al. Thorpe CT. Infection prophylaxis among patients with antineutrophil cytoplasmic antibody (ANCA) vasculitis: a scoping review. Clin Rheumatol. 2024 Jul 25.
[4] Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis. 2020 Jan;75(1):124-137.
[5] Takeda S, Watanabe-Kusunoki K, Nakazawa D, Kusunoki Y, Nishio S, et al. The pathogenicity of BPI-ANCA in a patient with systemic vasculitis. Front Immunol. 2019 Jun 12; 10:1334.
[6]Konda R, Rajasekaran A, Rizk DV. Antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Nephrol Hypertens. 2024 Sep 1;33(5):503-511.
[7]田新平,赵丽柯,姜振宇等.抗中性粒细胞胞质抗体相关血管炎诊疗规范[J].中华内科杂志, 2022,61(10) : 1128-1135.
[8] Kidney disease: Improving Global Outcomes (KDIGO) ANCA vasculitis work group. KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024 Mar;105(3S): S71-S116.
[9] Paroli M, Gioia C, Accapezzato D. New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond. Antibodies (Basel). 2023 Mar 21;12(1):25.
[10] Chung SA, Langford CA, Maz M, Abril A, Gorelik M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-1383.
